Parreira J M, Correia L G, Pereira E, Duarte R S, Pape E
Diabetes and Nutrition Clinic, Santa Maria Hospital, Lisbon, Portugal.
Am J Hypertens. 1993 Mar;6(3 Pt 2):104S-106S. doi: 10.1093/ajh/6.3.104s.
The aim of this study was to investigate the efficacy, tolerability, and safety of isradipine in hypertensive diabetic patients. Twenty-eight patients (14 men and 14 women), of whom 15 had type II (non-insulin-dependent) and 13 had type I (insulin-dependent) diabetes mellitus, received isradipine for 6 months. A significant reduction was observed in both systolic and diastolic blood pressures (P < .00005). There were no significant differences between the type I and type II diabetes patients; metabolic control remained stable. Moderate or slight headaches were reported by four patients. In conclusion, the overall efficacy of isradipine and its tolerability were found to be very good.
本研究的目的是调查伊拉地平在高血压糖尿病患者中的疗效、耐受性和安全性。28例患者（14名男性和14名女性），其中15例患有II型（非胰岛素依赖型）糖尿病，13例患有I型（胰岛素依赖型）糖尿病，接受伊拉地平治疗6个月。收缩压和舒张压均显著降低（P <.00005）。I型和II型糖尿病患者之间无显著差异；代谢控制保持稳定。4例患者报告有中度或轻度头痛。总之，伊拉地平的总体疗效及其耐受性非常好。
